...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs and aging >Targeted therapy for advanced hepatocellular cancer in the elderly: Focus on sorafenib
【24h】

Targeted therapy for advanced hepatocellular cancer in the elderly: Focus on sorafenib

机译：老年晚期肝细胞癌的靶向治疗：关注索拉非尼

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths worldwide. Worldwide progressive population aging demands consensus development for decision making when treating elderly patients. Age itself might not be a critical determinant for the selection of a therapeutic option. In the past few years, the mechanisms of hepato-carcinogenesis have been elucidated, and the involvement of a number of pathways, including angiogenesis, aberrant signal transduction, and dysregulated cell cycle control, have been demonstrated, leading to evaluation of the activity and toxicity of some of the new molecularly targeted agents. Sorafenib was demonstrated to significantly increase the survival of patients with advanced HCC in two prospective, randomized, placebo-controlled trials. Subsequently, a number of retrospective or prospective studies have indicated that the effectiveness of sorafenib therapy in the treatment of HCC is similar in elderly and non-elderly patients. The aim of this review is to describe the impact of age on the effects of sorafenib-targeted therapy in patients with HCC, and the next treatment options with new targeted agents (everolimus, tivantinib, linifanib, etc.).
机译：肝细胞癌（HCC）是全世界与癌症相关的死亡的第三大最常见原因。全球范围内的人口老龄化要求在治疗老年患者时就决策达成共识。年龄本身可能不是选择治疗方案的关键决定因素。在过去的几年中，已经阐明了肝癌的发生机制，并已证明涉及许多途径，包括血管生成，异常信号转导和细胞周期控制失调，从而可以评估其活性和毒性。一些新的分子靶向药物。在两项前瞻性，随机，安慰剂对照试验中，索拉非尼可显着提高晚期肝癌患者的生存率。随后，许多回顾性或前瞻性研究表明，索拉非尼治疗HCC的有效性在老年和非老年患者中相似。这篇综述的目的是描述年龄对肝癌患者索拉非尼靶向治疗效果的影响，以及新靶向药物（依维莫司，替维替尼，利尼法尼等）的下一种治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号